Adjust Font Sizing:

Industry News

Recent News:

April 11, 2024—Narcolepsy Network would like to share a press release that is posted on Harmony Biosciences’ website. This press release announces exclusive agreement to develop and commercialize TPM-1116, a highly potent and selective oral orexin-2 receptor agonist.

April 10, 2024—Narcolepsy Network would like to share a press release that is posted on Alkermes’ website. This press release announces positive topline results from phase 1b study of ALKS 2680 demonstrating improved wakefulness in patients with narcolepsy type 2 and idiopathic hypersomnia.

March 26, 2024—Narcolepsy Network would like to share a press release that is posted on Zevra Therapeutics’ website. This press release announces top-line data from the phase 2 clinical trial of KP1077 for idiopathic hypersomnia.

March 25, 2024—Narcolepsy Network would like to share a press release that is posted on Axsome Therapeutics’ website. This press release announces results of the CRESCENDO narcolepsy patient survey, demonstrating unmet needs in treated narcolepsy type 1 patients.

March 25, 2024—Narcolepsy Network would like to share a press release that is posted on Axsome Therapeutics’ website. This press release announces that AXS-12 achieves primary endpoint in the symphony phase 3 trial in narcolepsy type 1.

February 21, 2024—Narcolepsy Network would like to share a press release that is posted on Harmony Biosciences’ website. This press release indicates Food & Drug Administration grants priority review to Harmony Biosciences’ application for WAKIX® (pitolisant) in pediatric narcolepsy.

February 15, 2024—Narcolepsy Network would like to share an update from Takeda Pharmaceuticals regarding its intention to rapidly initiate the first Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024.

October 17, 2023—Narcolepsy Network would like to share recent news from Neurology Live regarding recent findings from Harmony Biosciences’ Phase 3 INTUNE Study Evaluating Pitolisant in Patients with Idiopathic Hypersomnia.

September 7, 2023—Narcolepsy Network would like to share a press release that is posted on Harmony Biosciences’ website. This press release indicates Food & Drug Administration orphan drug designation for pitolisant for treatment of idiopathic hypersomnia.